AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyObservationalTrial registry record – peer review not applicable
Observational Study on Patients with JCV Infection and PML
An observational study aimed to enroll 700 individuals with JCV infection and/or PML, planned to investigate their clinical and biological features over one year. No results have been posted yet, as the study is still in the planning phase without outcomes reported.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a trial registry record and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
Understanding the baseline features of patients with JCV infection and PML could help in developing better management strategies, as these conditions could have diverse presentations.
What this does not prove
The study has no posted results yet, and the endpoints outlined are not findings but rather planned objectives.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 700 · planned enrolment
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Individuals at least 2 years of age who have PML and participants considered at risk for PML.
- Size of effect
- Not reported
- Secondary endpoints
- To longitudinally follow patients with JCV infection and/or PML with thorough characterization of their clinical course, imaging correlates, immunological markers, and viral studies.
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
Supporting passages (12)
study designStudy type: Observational
sample sizeEnrollment: 700 participants (estimated)
primary endpointPrimary endpoints: To characterize the baseline presentation of patients with JCV infection and/or PML with regard to clinical, radiological, immunological, genetic and viral features.
populationIndividuals at least 2 years of age who have PML.
secondary endpoints"measure": "To longitudinally follow patients with JCV infection and/or PML with thorough characterization of their clinical course, imaging correlates, immunological markers, and viral studies",
limitationsPlanned enrolment and endpoints are not findings.
limitationsNo results are posted.
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
subjectsParticipants: people; ages from 2 Years to 120 Years; sex All
follow upFollow-up: one year following last enrollment
sample size basisEnrollment: 700 participants (estimated)
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.